A Phase 1b, Multicenter, Single Dose Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Subjects in the United States
Latest Information Update: 06 May 2025
At a glance
- Drugs Patidistrogene bexoparvovec (Primary)
- Indications Limb girdle muscular dystrophies
- Focus Adverse reactions; Proof of concept
- Acronyms DISCOVERY
- Sponsors Sarepta Therapeutics
Most Recent Events
- 15 Apr 2025 According to a Sarepta Therapeutics media release, enrollment and dosing is complete in this trial.
- 15 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.